Nasdaq:PGNY
Progyny, Inc.
A premier US-based provider of fertility care insurance and reproductive health solutions leveraging a unique data-driven platform.
Key Metrics
Investment Thesis
Bull Case
Investors may find value in Progyny's dominant market position within a secularly growing fertility care industry expected to expand as reproductive health awareness increases. The company's robust cash generation capabilities evidenced by $210M operating cash flow and strategic share repurchases of $81.7M suggest confidence in long-term growth prospects despite recent net changes in cash. Differentiated technology platform creates sustainable competitive moat that could yield expanding margins as the company scales its insured population base.
Bear Case
Concerns regarding potential regulatory headwinds on reproductive healthcare services could materially impact future revenue streams and operational scalability. High levels of other investing outflows including $541.7M in non-operating activities alongside significant cash reserves changes may indicate strategic uncertainty or aggressive M&A that could dilute shareholder value. Revenue growth has slowed from the double-digit expansion seen in early years, suggesting market saturation risks as the company approaches its mature stage in developed markets.
About Progyny, Inc.
Progyny (PGNY) is a leading provider of fertility care insurance solutions and specialized reproductive health products serving the United States market. The company primarily operates through its proprietary insurance platform and direct-to-consumer pharmaceutical distribution channels. Key revenue drivers include its comprehensive fertility benefits plans and prescription management services for infertility treatments.
Analysis
Management Discussion
Recent financial performance demonstrates resilience with revenue reaching $1.29B in 2025, reflecting a consistent upward trend from $786.9M in 2022 despite minor fluctuations in net income between $54M and $62M over the past four years. The company successfully generated $210.2M in operating cash flow while managing substantial investing outflows of $159M likely tied to strategic acquisitions and marketable security purchases totaling $355M. Strong gross profit margins supported by high revenue growth indicate effective cost management relative to the expanding addressable market.
Industry Overview
The global fertility care industry represents a multi-billion dollar opportunity driven by delayed parenthood trends and increasing acceptance of assisted reproductive technologies. US market leaders benefit from high switching costs and specialized knowledge barriers that create favorable long-term operating environments for established players. Consolidation trends favor well-capitalized incumbents who can integrate disparate service offerings into comprehensive platforms while smaller competitors struggle with compliance complexities.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $786.9M | $1.09B | $1.17B | $1.29B |
| Cost of Revenue | $619.6M | $849.8M | $913.9M | $984.2M |
| Gross Profit | $167.3M | $238.8M | $253.4M | $304.5M |
| Operating Expenses | $144.0M | $176.6M | $185.9M | $219.2M |
| Operating Income | $23.3M | $62.2M | $67.5M | $85.3M |
| R&D | — | — | — | $9.5M |
| G&A | $98.3M | $117.1M | $122.0M | $147.1M |
| Marketing | $45.7M | $59.5M | $63.9M | $72.1M |
| Stock-Based Comp | $100.7M | $122.6M | $128.1M | $131.9M |
| D&A | $1.6M | $2.3M | $3.2M | $4.9M |
| Depreciation | $1.1M | $2.2M | $3.1M | $4.1M |
| Amortization | $500.0K | $100.0K | $100.0K | $800.0K |
| Other OpEx | $0 | $0 | $0 | $-9.5M |
| Non-Operating Income | $1.1M | $8.5M | $15.7M | $10.2M |
| Pre-Tax Income | $24.4M | $70.7M | $83.2M | $95.4M |
| Income Tax | $-5.9M | $8.7M | $28.9M | $36.9M |
| Continuing Ops | $30.4M | $62.0M | $54.3M | $58.5M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $30.4M | $62.0M | $54.3M | $58.5M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $30.4M | $62.0M | $54.3M | $58.5M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $433.9M | $640.4M | $472.7M | $551.8M |
| Cash & Equivalents | $120.1M | $97.3M | $162.3M | $112.2M |
| Accounts Receivable | $240.1M | $241.9M | $235.3M | $220.3M |
| Prepaid Expenses | $4.5M | $27.5M | $9.4M | $21.4M |
| Other Current Assets | $69.2M | $273.8M | $65.6M | $197.9M |
| Long-Term Assets | $109.1M | $116.2M | $134.4M | $190.7M |
| PP&E (Net) | $8.4M | $10.2M | $12.4M | $29.9M |
| Goodwill | $11.9M | $11.9M | $15.5M | $20.0M |
| Operating Leases | $6.9M | $17.6M | $17.3M | $25.0M |
| Other LT Assets | $82.0M | $76.5M | $89.2M | $115.8M |
| Total Assets | $543.0M | $756.6M | $607.1M | $742.4M |
| Current Liabilities | $159.5M | $185.9M | $168.6M | $202.4M |
| Accounts Payable | $109.3M | $125.4M | $95.1M | $124.1M |
| Current Leases | $1.2M | $2.1M | $2.9M | $3.7M |
| Other Current Liab | $49.0M | $58.4M | $70.7M | $74.6M |
| Long-Term Liabilities | $6.5M | $17.2M | $16.4M | $24.0M |
| LT Operating Leases | $6.5M | $17.2M | $16.4M | $24.0M |
| Other LT Liab | $0 | $0 | $0 | $0 |
| Total Liabilities | $166.0M | $203.2M | $185.0M | $226.4M |
| Shareholders' Equity | $377.0M | $553.4M | $422.1M | $516.0M |
| Retained Earnings | $27.9M | $90.0M | $144.3M | $202.8M |
| AOCI | $501.0K | $2.8M | $39.0K | $498.0K |
| Total L&E | $543.0M | $756.6M | $607.1M | $742.4M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $30.4M | $62.0M | $54.3M | $58.5M |
| Non-Cash Adjustments | $-131.1M | $56.2M | $153.7M | $96.1M |
| Working Capital Changes | $181.2M | $70.6M | $-28.9M | $55.5M |
| Cash from Operations | $80.4M | $188.8M | $179.1M | $210.2M |
| Capital Expenditures | $3.2M | $3.6M | $5.4M | $18.4M |
| Cash from Investing | $-43.9M | $-200.5M | $195.8M | $-159.0M |
| Share Buybacks | — | — | $300.3M | $81.7M |
| Cash from Financing | $-7.9M | $-11.1M | $-309.9M | $-99.4M |
| FX Effect | $0 | $1.0K | $1.0K | $62.0K |
| Net Change in Cash | $28.7M | $-22.8M | $65.0M | $-48.1M |
| Beginning Cash | $91.4M | $120.1M | $97.3M | $162.3M |
| Ending Cash | $120.1M | $97.3M | $162.3M | $114.2M |
Frequently Asked Questions
How does Progyny, Inc. make money?
The company generates revenue primarily through its proprietary fertility insurance platform which offers customized coverage to employers and individuals, alongside its direct-to-consumer sales of fertility medications and related medical products. Additionally, Progyny provides specialized reproductive healthcare services including egg freezing and surrogacy matching programs that complement its core insurance offerings.
What are the main risks for PGNY?
Regulatory scrutiny regarding reproductive healthcare access could impact demand for fertility services and insurance products in certain jurisdictions. Intense competition from emerging direct-to-consumer telehealth providers and traditional insurers seeking to enter the specialty fertility market poses pricing pressure risks. Dependence on third-party pharmaceutical manufacturers exposes the company to supply chain disruptions and margin compression if drug acquisition costs rise significantly.
What is PGNY's competitive advantage?
Progyny maintains a significant first-mover advantage in the US fertility insurance market with a proprietary data analytics platform that optimizes coverage utilization and lowers claim costs for partners. The company benefits from strong network effects as increased partner adoption enhances its drug pricing leverage and expands its patient referral ecosystem. High switching costs for employers and individuals due to comprehensive coverage options create a durable customer retention base.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.